Next Article in Journal / Special Issue
Small Molecules Present in the Cerebrospinal Fluid Metabolome Influence Superoxide Dismutase 1 Aggregation
Previous Article in Journal
Adverse Impact of Diet-Induced Hypercholesterolemia on Cardiovascular Tissue Homeostasis in a Rabbit Model: Time-Dependent Changes in Cardiac Parameters
Previous Article in Special Issue
The Role of Initial Oligomers in Amyloid Fibril Formation by Human Stefin B
Review

Single-Chain Fragment Variable Passive Immunotherapies for Neurodegenerative Diseases

1
Department of Neuroscience, Georgetown University Medical Center, Washington, DC 20057, USA
2
Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2013, 14(9), 19109-19127; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms140919109
Received: 7 August 2013 / Revised: 29 August 2013 / Accepted: 30 August 2013 / Published: 17 September 2013
(This article belongs to the Collection Protein Folding)
Accumulation of misfolded proteins has been implicated in a variety of neurodegenerative diseases including prion diseases, Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD). In the past decade, single-chain fragment variable (scFv) -based immunotherapies have been developed to target abnormal proteins or various forms of protein aggregates including Aβ, SNCA, Htt, and PrP proteins. The scFvs are produced by fusing the variable regions of the antibody heavy and light chains, creating a much smaller protein with unaltered specificity. Because of its small size and relative ease of production, scFvs are promising diagnostic and therapeutic reagents for protein misfolded diseases. Studies have demonstrated the efficacy and safety of scFvs in preventing amyloid protein aggregation in preclinical models. Herein, we discuss recent developments of these immunotherapeutics. We review efforts of our group and others using scFv in neurodegenerative disease models. We illustrate the advantages of scFvs, including engineering to enhance misfolded conformer specificity and subcellular targeting to optimize therapeutic action. View Full-Text
Keywords: scFv; immunotherapy; Prion disease; Alzheimer’s disease; Parkinson’s disease; Huntington’s disease; PrP; Aβ; SNCA; Htt scFv; immunotherapy; Prion disease; Alzheimer’s disease; Parkinson’s disease; Huntington’s disease; PrP; ; SNCA; Htt
Show Figures

MDPI and ACS Style

Huang, L.; Su, X.; Federoff, H.J. Single-Chain Fragment Variable Passive Immunotherapies for Neurodegenerative Diseases. Int. J. Mol. Sci. 2013, 14, 19109-19127. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms140919109

AMA Style

Huang L, Su X, Federoff HJ. Single-Chain Fragment Variable Passive Immunotherapies for Neurodegenerative Diseases. International Journal of Molecular Sciences. 2013; 14(9):19109-19127. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms140919109

Chicago/Turabian Style

Huang, Liang, Xiaomin Su, and Howard J. Federoff 2013. "Single-Chain Fragment Variable Passive Immunotherapies for Neurodegenerative Diseases" International Journal of Molecular Sciences 14, no. 9: 19109-19127. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms140919109

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop